Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 0 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $14.0, a high estimate of $20.00, and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 27.27% from the previous average price target of $11.00.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of...
Login or create a forever free account to read this news
Sign up/Log in